Beike Biotech of Shenzhen Unveils Cancer Immunotherapy Program

Beike Biotechnology, a Shenzhen company usually known for its stem cell products, declared that it has built a "strategic position" in cancer immunotherapy. In 2014, Beike acquired China rights to an immunotherapy from Altor Biosciences of Florida. One year later, the company acquired Nanjing Abingen Biotech, also an immunotherapy company. By adding its own R&D to its acquired technologies, Beike believes it can build a portfolio of cancer immunotherapies for China in the next few years. More details.... Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.